ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceutical products. The company employs 501-1,000 people and operates multiple manufacturing locations across the United States, with sites in Baudette, Minnesota, Princeton, New Jersey, and East Windsor, New Jersey.
Its manufacturing capabilities span hormone manufacturing, solid dose and liquid dose production, controlled substances, contract manufacturing, and packaging, supported by research and development in both generic and branded drug development. The company serves healthcare providers, pharmacists, and patients, and states a focus on delivering essential medications through its U.S. manufacturing base.
ANI is undergoing a transformation into a rare disease company focused on conditions with high unmet medical need. Its lead rare disease asset is Purified Cortrophin® Gel. The broader portfolio includes branded prescription pharmaceutical products and a generic business being strengthened through enhanced research and development capability. Industry verticals in which the company operates include biopharmaceuticals, rare disease, generics, ophthalmology, nephrology, acute care, and contract manufacturing.
Headquartered operations are spread across several U.S. locations, and the company is publicly traded on Nasdaq under the ticker ANIP.
